–
88/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Growth Hormone · GHRP
Ipamorelin
Released: Last reviewed:
Ipamorelin is a pentapeptide growth hormone-releasing peptide with high selectivity for GH release and minimal effect on prolactin, cortisol, or appetite. The most-prescribed GHRP in modern peptide protocols.
Ipamorelin at a glance
Ipamorelin is a pentapeptide growth hormone-releasing peptide with high selectivity for GH release and minimal effect on prolactin, cortisol, or appetite. The most-prescribed GHRP in modern peptide protocols. Mechanism: GHRP / GH secretagogue (selective). Typical route: Subcutaneous. FDA status: Not FDA-approved. Dispensed by compounding pharmacies; the most common GHRP in current clinical and telehealth practice.
Drug classGHRP / GH secretagogue (selective)
Half-life~2 hours
RouteSubcutaneous
Common dosing100-300 mcg, 2-3x/day
FDA statusNot approved
Available throughSee the dated FDA status notice above
Mechanism of action
Ipamorelin selectively activates the ghrelin receptor on pituitary somatotrophs, stimulating GH release with minimal off-target effects. Its clean side-effect profile makes it the preferred choice for long-term GH-support protocols, usually paired with CJC-1295.
Dosing reference
Subcutaneous: 100-300 mcg, two to three times daily. Most common protocol is CJC-1295 + Ipamorelin combined at 100 mcg + 100 mcg per dose, taken on empty stomach and before bed.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Dispensed by compounding pharmacies; the most common GHRP in current clinical and telehealth practice.
U.S. telehealth providers that work with Ipamorelin
–
80/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
85/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
76/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Related growth hormone secretagogues peptides
Frequently asked questions about Ipamorelin
Why is Ipamorelin combined with CJC-1295?
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. The two act on different receptors and produce a larger, more sustained GH pulse together than either alone.
Is Ipamorelin safe long-term?
Long-term human safety data is limited. The clean side-effect profile is its primary advantage over other GHRPs, but multi-year use should be physician-monitored.
References
- Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
- The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28526632
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.